Newsroom

Dear Provider,

Model of Care Training is Required

The Centers for Medicare & Medicaid Services (CMS) requires health plans to provide annual education and training on our Special Need’s Plans (SNP) Model of Care to providers who treat our SNP members. This applies to our Dual Eligible Special Needs Plan (D-SNP) members, who are eligible for both Medicare and Medicaid, and our Chronic Condition Special Needs Plan (C-SNP) members.

As stated in the Provider Manual, all providers who treat our SNP members regardless of network participation status must complete Model of Care (MOC) training annually by December 31st of each year.

The training is designed to help you better understand our approach to the delivery of care for SNP members.

How to access the training

The SNP MOC training is available for download and self-study at: https://www.wellcare.com/Providers/Model-of-Care-Training.

We appreciate the quality care you provide to our members and your support of our efforts to meet CMS regulations.

For additional information on how to work with our health plan to manage SNP members, please visit our Provider Resources page(s) at  https://www.wellcare.com/Providers/Model-of-Care-Training. This site has links to the Provider Manual, Quick Reference Guides, Clinical Practice Guidelines, and more.

Step Therapy programs are developed by Wellcare's P&T Committee. They encourage the use of therapeutically equivalent, lower-cost medication alternatives (first-line therapy) before “stepping up” to alternatives that are usually less cost-effective.

Step Therapy programs are intended to be a safe and effective method of reducing the cost of treatment by ensuring that an adequate trial of a proven safe and cost-effective therapy is attempted before progressing to a more costly option. First-line drugs are recognized as safe, effective, and economically sound treatments.

The first-line drugs on Wellcare’s formulary have been evaluated through the use of clinical literature and are approved by Wellcare’s P&T Committee. Step therapy is failure of at least one different or less expensive drug prior to coverage of a drug on this list. 

Drugs requiring step therapy effective January 01, 2024 are listed below. The prescriber, patient, or authorized representative may ask for an exception. Step therapy applies if the drug has not been used in the past 365 days.

Drug Name                                                       

Abatacept (Orencia®)

Ado-trastuzumab emtansine (Kadcyla®)

Aflibercept (Eylea®)

Atezolizumab (Tecentriq®)

Axicabtagene ciloleucel (Yescarta®)

Bevacizumab (Avastin®, Alymsys®, Mvasi®, Vegzelma, Zirabev)

Brentuximab vedotin (Adcetris®)

Brexucabtagene autoleucel (Tecartus)

Brolucizumab-dbll (Beovu®)

Cemiplimab-rwlc (Libtayo®)

Certolizumab (Cimzia®)

Ciltacabtagene autoleucel (Carvykti)

Corticosteroid intravitreal implants: dexamethasone (Ozurdex®), fluocinolone acetonide (Iluvien®, Retisert®, Yutiq)

Corticotropin (H.P. Acthar®, Purified Cortrophin Gel)

Daratumumab (Darzalex®), daratumumab/hyaluronidase-fihj (Darzalex Faspro)

Darbepoetin alfa (Aranesp®)

Denosumab (Xgeva®)

Durvalumab (Imfinzi®)

Eflapegrastim-xnst (Rolvedon)

Elotuzumab (Empliciti®)

Emapalumab-lzsg (Gamifant)

Epoetin alfa (Epogen®, Procrit®)

Faricimab-svoa (Vabysmo)

Ferric carboxymaltose (Injectafer®)

Ferric derisomaltose (Monoferric®)

Ferric pyrophosphate (Triferic®, Triferic Avnu®)

Ferumoxytol (Feraheme®)

Filgrastim (Neupogen®, Zarxio®, Nivestym, Granix®, Releuko®)

Golimumab (Simponi®, Simponi Aria®)

Hyaluronate derivatives: sodium hyaluronate (Euflexxa®, Gelsyn-3, GenVisc®850, Hyalgan®, Supartz FX, Synojoynt, Triluron, TriVisc, VISCO-3), hyaluronic acid (Durolane®), cross-linked hyaluronate (Gel-One®), hyaluronan (Hymovis®, Orthovisc®, Monovisc®), hylan polymers A and B (Synvisc®, Synvisc One®)

Idecabtagene vicleucel (Abecma)

Immune globulins (Asceniv, Bivigamâ, Cutaquigâ, Cuvitru, Flebogammaâ DIF, GamaSTANâ, GamaSTANâ S/D, Gammagardâ liquid, Gammagardâ S/D, Gammaked, Gammaplexâ, Gamunexâ-C, Hizentra®, HyQviaâ, Octagamâ, Panzygaâ, Privigenâ, Xembifyâ)

IncobotulinumtoxinA (Xeomin®)

Lisocabtagene maraleucel (Breyanzi®)

Lurbinectedin (Zepzelca)

Luspatercept-aamt (Reblozyl®)

Lutetium Lu 177 dotatate (Lutathera®)

Nadofaragene firadenovec-vncg (Adstiladrin®)

Natalizumab (Tysabri®)

Nivolumab (Opdivo®)

Pegfilgrastim (Neulasta®, Fulphila, Fylnetra®, Nyvepria, Stimufend®, Udenyca, Ziextenzo)

Pembrolizumab (Keytruda®)

Polatuzumab vedotin-piiq (Polivy)

Ramucirumab (Cyramza®)

Ranibizumab (Lucentis®, Byooviz®, Cimerli, Susvimo)

RimabotulinumtoxinB (Myobloc®)

Rituximab (Rituxan®, Riabni, Ruxience, Truxima®), rituximab/hyaluronidase (Rituxan Hycela)

Romiplostim (Nplate®)

Romosuzumab-aqqg (Evenity)

Sargramostim (Leukine®)

Sipuleucel-T (Provenge®)

Teclistamab-cqyv (Tecvayli®)

Teprotumumab-trbw (Tepezza)

Tisagenlecleucel (Kymriah®)

Tocilizumab (Actemra®)

Trastuzumab (Herceptin®, Ontruzant®, Herzuma®, Ogivri, Trazimera, Kanjinti), trastuzumab/hyaluronidase (Herceptin Hylecta)

Triamcinolone ER injection (Zilretta®)

Triamcinolone acetonide suprachoroidal injection (Xipere)

Vedolizumab (Entyvio®)

Verteporfin (Visudyne®)

 

Medicare Prior Authorization

List effective 10/1/2023

Wellcare Oklahoma requires prior authorization (PA) as a condition of payment for many services.  This Notice contains information regarding such prior authorization requirements and is applicable to all Medicare products offered by Wellcare.

Wellcare is committed to delivering cost effective quality care to our members.  This effort requires us to ensure that our members receive only treatment that is medically necessary according to current standards of practice.  Prior authorization is a process initiated by the physician in which we verify the medical necessity of a treatment in advance using independent objective medical criteria and/or in network utilization, where applicable.

It is the ordering/prescribing provider’s responsibility to determine which specific codes require prior authorization.

 

Please verify eligibility and benefits prior to rendering services for all members. Payment, regardless of authorization, is contingent on the member’s eligibility at the time service is rendered. NON-PAR PROVIDERS & FACILITIES REQUIRE AUTHORIZATION FOR ALL HMO SERVICES EXCEPT WHERE INDICATED.       

For complete CPT/HCPCS code listing, please see Online Prior Authorization Tool on our website at WellcareOK.com.

 

Effective October 1st, 2023, the following are changes to prior authorization requirements

 

 

Service Category

 

PA Rule

Services

Procedure Codes

Audiology

No PA Required

Pure tone audiometry 

0208T, 0209T

Behavioral Health

No PA Required

Alcohol and/or drug services

H0010, H0011, H0012, H0014, H0016, H0018

Assertive community treatment, face-to-face

H0039

BH and Community Support Services

H2001, H2012, H2016, H2018, H2020, H2022, H2030, H2034, H2036

Crisis intervention mental health services, per hour

S9484, S9485

Adaptive behavior treatment

97157

Breast Reconstruction

No PA Required

Repair and/or reconstruction

19357, 19367, 19368, S2068

Cardiovascular

PA Required

Coronary intravascular lithotripsy (IVL) procedure

0715T

Pacemaker/cardioverter-defibrillator devices and procedures

C1899, G0448

No PA Required

Device interrogation and analysis

0418T

Transcatheter valve and cardiac procedures

0483T, 0569T, 0644T

DME & Supplies

PA Required

Hospital bed and mattress

E0302, E0372, E0462

Respiratory systems and supplies

E0440, E0467

Patient lifts

E0639

Pneumatic & non-pneumatic compressor devices

E0657, E0665, E0666, E0669, E0670, E0672, K1024, K1033

Ultraviolet light therapy

E0691, E0694

Wheelchairs, power operated vehicles, and accessories

E0983, E0985, E0988, E1004, E1036, E1070, E1084, E1087, E1170, E1222, E1223, E1228, E1239, E1270, E1280, E1296, E1298, E2328, E2341, E2343, E2358, E2362, E2364, E2368, E2369, E2610, E2614, E2625, E2631, E2632, E2633, K0008, K0009, K0011, K0012, K0014, K0015, K0046, K0065, K0098, K0669, K0802, K0807, K0812, K0814, K0815, K0829, K0850, K0851, K0852, K0853, K0860, K0864, K0877, K0878, K0884, K0891, K0898, K0899

Nerve stimulating device

K1018

Speech generating device/accessory

E2502

Automatic external defibrillator

K0606

No PA Required

Compression burn garment

A6507

Hospital bed, mattress, and supplies

E0181, E0182, E0189, E0305, E0310, E0316, E0328

Electronic bowel irrigation system

E0350

Delivery/installation charges for hemodialysis equipment

E1600

Heat, cold, and light therapies

E0202, E0217, E0221

Respiratory systems, devices and supplies

A7047, E0435, E0455, E0472, E0500

Breast pump, hospital grade, electric

E0604

Monitoring equipment

E0619, E0620

Functional electrical stimulator

E0770

Traction and other orthopedic devices

E0856, E0944

 

 

 

 

Wheelchairs and accessories

E0968, E0969, E0980, E0994, E1014, E1029, E1092, E1093, E1160, E1229, E1232, E1233, E1234, E1235, E1236, E1237, E1238, E2291, E2292, E2293, E2294, E2301, E2324, E2381, E2382, E2384, E2385, E2386, E2387, E2388, E2389, E2390, E2391, E2392, E2394, E2395, E2396, K0017, K0018, K0020, K0053, K0105, K0195

Blood glucose monitor

E2100, E2102

Evaluation & Management

No PA Required

Nursing facility care plan oversight

99306, 99379

Medication therapy management

99605, 99606, 99607

General Surgery

PA Required

Repair procedures on the nose

30410, 30420, 30430, 30520

Procedures on the stomach

43881 

Procedures on the penis

54400, 54401, 54405

Phrenic nerve stimulation system procedure

0435T

Benign thyroid nodule ablation

0673T

No PA Required, unless managed by a vendor in select markets

Removal of abdominal mesh

11008

Removal of skin tags procedures

11200, 11201

Skin color correction

11920, 11921, 11922

Tissue expanders

11960, 11970, 11971 

Skin therapies

15786, 15787, 17360

Trigger point injections

20552, 20553

Cranial/facial repairs

21175, 21181, 21183, 21193, 21230, 21256, 21280

Repair procedures on the nose

30460, 30462, 30560, 30630

 

Transplant related procedures

32855, 32856, 33933, 33940, 33944, 38206, 38207, 38208, 38209, 38214, 38215, 38230, 47143, 48551, 48552, 50300, 50320, 50323, 50325, 50327, 50328, 50329, 50370

Repair procedures on the urethra

52010, 52301, 52343, 53420

Excision procedures on the endocrine system

60212, 60505

Procedures on the spine/spinal cord

22527, 62367, 62368, 62370

Procedures on the cardiovascular system

33952, 36836, 36837

Procedures on the spleen

38129

Procedures on the diaphragm

39599

Procedures on the digestive system

43283, 43772, 43774, 44145, 64595

Neurostimulator procedures on the peripheral nerves

64585

GI Services

No PA Required

Transnasal EGD

0652T, 0653T

Gynecology

No PA Required

Excision/repair of the vulva, vagina

56625, 57291, 57292

Hysterectomy procedures

58150, 58152, 58180, 58200, 58210, 58240, 58260, 58262, 58263, 58270, 58275, 58280, 58290, 58291, 58292, 58541, 58542, 58543, 58544, 58548, 58550, 58552, 58553, 58554, 58570, 58571, 58572, 58573, 58575, 58951, 58953, 58954, 58956

Myomectomy, ovarian/tubal resection

58545, 58546, 58661, 58720, 58940, 58952

Home Care

No PA Required

Home care services

S5145, S5150

Contracted home health

T1022

Injection Procedures

PA Required

Percutaneous lumbar intravertebral disc injection

0627T, 0628T

No PA Required

Injection of the spine/spinal cord

62280, 62290, 62291, 62324, 62325, 62326, 62327

Maternity

No PA Required

Maternity care

59866, 59897

Medicine Services & Procedures

No PA Required, unless managed by a vendor in select markets

Instillation, bupivacaine and meloxicam, 1 mg/0.03 mg

C9088

Immune globulins, serum or recombinant product

90283

Special otorhinolaryngologic procedures

92512, 92516, 92520, 92546, 92597, 92607, 92608, 92609, 92610, 92700

Neurology testing

95700, 95803

Chiropractic treatment

98940, 98941, 98942

Education and training for patient self-management

98960

Nutrition

No PA Required

Medical nutrition therapy

97804

Enteral formulas and additives

B4157, B4158, B4159, B4162, B9006

Medical foods for inborn errors of metabolism

S9435

Orthopedics

PA Required

Insertion sinus tarsi implant

0335T

Sacroiliac joint arthrodesis procedure

0775T

Ophthalmology

No PA Required

Open–eye eyelid treatment device 

0563T

Other procedures on the cornea

65765

Orthotics and Prosthetics

PA Required

Spinal orthotics

L0458, L0468, L0480, L0484, L0632, L0638, L0639, L0640, L0651, L1200, L1300

Lower extremity orthotics

E1830, L1690, L1840, L1904, L2000, L2005, L2030, L2034, L2038, L2525, L2627, L2628

Upper extremity orthotics

E1802, E1818, E1840

Lower extremity prosthetics

K1014, L5010, L5060, L5200, L5505, L5510, L5520, L5535, L5560, L5570, L5600, L5610, L5614, L5628, L5630, L5638, L5639, L5640, L5661, L5682, L5702, L5795, L5818, L5824, L5826, L5830, L5858, L5859, L5930, L5966, L5969, L5982, L5990

Upper extremity prosthetics

L6000, L6010, L6020, L6200, L6250, L6320, L6400, L6623, L6628, L6638, L6646, L6647, L6692, L6697, L6704, L6711, L6712, L6883, L6885, L6895, L6900, L6905, L6910, L6920, L6925, L6940, L6945, L6950, L6965, L7405

Cochlear device

L8614

Orbital prosthetics

L8042

Unlisted prosthetics

L8499

No PA Required

Penile devices

C2622, L7900

Spinal orthotics

L0700, L0710

Upper extremity orthotics

L0170, L0190, L3671, L3674, L3962

Lower extremity orthotics

L0469, L0470, L1000, L1270, L1640, L1730, L1847, L1860, L2126, L2136, L2570, L2580

Cochlear implant device components

L8627, L8628, L8629

Pretibial shell

L4130

Prosthetic fitting, immediate post-surgical

L5400, L5420, L5430

Nasal and facial prosthesis

L8040, L8046, V2629

Finger prosthetics

L8659

Pain Management

PA Required

Percutaneous cranial nerves stimulation

0720T

Injection of anesthetic agent (nerve block)

64450, 64451, 64494

Destruction by neurolytic agent

64624

Pathology and Laboratory

PA Required

Genetic analysis  

81265, 81266

No PA Required

Multianalyte assays

0014M

Proprietary laboratory analyses

0035U, 0040U, 0219U, 0353U

Therapeutic drug assays

80220

Genetic analysis  

81224, 81239, 81262, 81316, 81341

Multianalyte assays w/algorithmic analyses

81508, 81511, 81512, 81513, 81514, 81528

Chemistry procedures

82077, 82105, 82397, 82657, 82677, 84163, 84702, 84704, 84999

Qualitative or semiquantitative immunoassays

86152, 86336

Postmortem examination

88025

Flow cytometry, cytogenetic studies

88182, 88230, 88233, 88235, 88237, 88263, 88269, 88291

Surgical pathology

88364, 88365, 88366, 88367, 88368, 88369, 88373, 88374, 88377, 88381

Reproductive medicine

89310, 89320, 89321

Pharmacy

No PA Required

Pharmacy dispensing fee for inhalation drug(s)

Q0513, Q0514

Pharmacy compounding and dispensing services

S9430

Professional Services

No PA Required

Molecular pathology procedure; physician interpretation and report

G0452

Hospital observation service and admission

G0378, G0379

Radiology Services

No PA Required – except when managed by vendor in select markets

PET imaging, any site, NOS

G0235

ERCP with endomicroscopy

0397T

Quantitative ultrasound tissue characterization

0690T

Fetal MRI

74713

Endocrine system

78012, 78013, 78014, 78018, 78070, 78071, 78072

Bone marrow imaging

78102

Gastrointestinal system

78201, 78202, 78215, 78216, 78226, 78227

Cardiovascular system

75565, 78434

Radiopharmaceutical localization of tumor

78800, 78804

Radiopharmaceuticals

PA Required

Lutetium lu 177 vipivotide tetraxetan, therapeutic

A9607

No PA Required

Radiopharmaceutical, diagnostic, not otherwise classified

A4641

Fluorodeoxyglucose F-18 FDG, diagnostic, per study dose

A9552

Rubidium Rb-82, diagnostic, per study dose

A9555

Skin Substitute

PA Required

Skin substitute products

Q4199

No PA Required

Autograft suspension

C1832

Specialty Medications                                                                 

PA Required

Injectable Medication

J1950, J2182, J2786, J9214, J9044

Intravitreal implant

J7313

Hyaluronic injections

J7322, J7328

No PA Required

Inhalation medications

J7605, J7606, J7626

Injectables

J0121, J0572, J0573, J0574, J1750, J1756, J2212, J2440, J1453, J3489, S0039, S0080

Other medication

S0091, S0157

Therapy Services

No PA Required, unless managed by a vendor in select markets

Physical medicine and rehab evaluations

97164, 97168, 97169, 97170, 97172, 97750

Occupational therapy services, qualified occupational therapist

G0129

Speech, language, dysphagia screenings

V5362, V5363, V5364

Electrical stimulation, (unattended)

G0281, G0282

Wound Care

PA Required

Active wound care management – PA required after 12 combined wound care visits per calendar year

97597, 97598, 97602

Electrical stimulation and cutaneous wound healing

0512T

Matrix for wound management

A2001, A2002, A2004, A2005, A2007, A2015

 

Who is Express Scripts?

Express Scripts is a pharmacy benefit management (PBM) company serving more than 100 million Americans. Express Scripts Pharmacy delivers specialized care that puts patients first through a smarter approach to pharmacy services.

What is the rationale for changing PBM vendors?

Express Scripts as our PBM will bring increased levels of transparency and value, positioning us to provide the highest level of quality at the lowest possible cost to our members.

What PBM services will Express Scripts be providing?

Express Scripts will be the PBM of record providing pharmacy claims adjudication, pharmacy network administration and rebate administration on behalf of our health plan.

How will this PBM transition impact our members?

There will be no immediate change in service for our members, although they will receive new ID cards. We will continue to provide the same member-focused care and support as we do today.

Our highest priority continues to be serving all our members, and we remain committed to providing affordable quality healthcare services. Our team is working closely with both CVS and Express Scripts to ensure a seamless migration.

Is Amazon part of the Express Scripts Network?

Yes, Amazon is part of the Express Scripts network.

Can members still use CVS Caremark for their mail orders?

No, CVS Caremark Mail Service Pharmacy will be out of network, effective January 1, 2024. If members wish to continue using mail order in 2024, they must switch to Express Scripts Pharmacy.

Do members have a choice besides Express Scripts for mail order services?

Members have a choice to use other pharmacies that offer home delivery but Epress Scripts Pharmacy is the preferred mail order pharmacy for our health plan.

Are we communicating this mail order change to members?

Yes. Impacted Medicaid members will receive a Mail Order Change notification letter.

How will members get started with mail order at Express Scripts?

For existing mail order users:

  • Most open prescription refills will be automatically transferred to Express Scripts
  • Refills for controlled drugs, such as Alprazolam, Clonazepam, Pregabalin, Tramadol, Zolpidem, etc., will not automatically transfer to Express Scripts Pharmacy; members must request a new prescription from their provider

For new mail order prescriptions on or after January 1, 2024, members may do one of the following:

  • Ask their provider to electronically submit or fax a new prescription to Express Scripts Pharmacy, as listed on their medical ID cards
  • Visit express-scripts.com/rx to register or sign in, then follow the guided steps to request a prescription
  • Call Express Scripts Pharmacy, who will contact their provider for a new prescription to be filled via mail order
  • Mail a Home Delivery Order Form (available at express-scripts.com/rx) directly to Express Scripts Pharmacy

Does Express Scripts offer a mail order app?

Yes, members will be able to download the Express Scripts Pharmacy app, available on the App Store and Google Play. Members with a mail order benefit can order medications, track delivery and more.

 

 

PRO_ 2435207_E_Internal Approved 10102023                                                  

We are pleased to announce that, effective January 1, 2024, Express Scripts® will begin processing pharmacy claims for our plan members.

Express Scripts is a pharmacy benefit management (PBM) company serving more than 100 million Americans. Express Scripts Pharmacy delivers specialized care that puts patients first through a smarter approach to pharmacy services.

Members have been notified in advance and will receive a new ID card with updated pharmacy information, so that they are prepared to begin having their prescriptions filled at participating network pharmacies when this change occurs.

Providers can direct members to call the Member Services phone number listed on their ID card should they have questions about this change.

Please contact your Provider Relations Representative with any additional questions.

Thank you for the care you provide to our members.

 

 

 

PRO_2433922E_State/Internal Approved 09272023                                                         

Earlier this year, the Biden Administration announced that the federal Public Health Emergency (PHE) related to the COVID-19 pandemic will end on May 11, 2023.

During the PHE, we followed guidance from the Centers for Medicaid & Medicare Services (CMS) and instituted temporary waivers for select services. This action ensured that critical care could be quickly delivered to our members during a time of heightened need. Beginning May 12, 2023, these temporary waivers will expire, and our members’ Medicare plan benefits will be reinstated for the following services:

 

Service

Member Liability

Prior Auth Needed?

COVID-19 Testing and Screening

(Administered by Provider)

Per member plan benefits

No

COVID-19 Vaccinations

$0 member cost-share for

vaccine administration*

No

COVID-19 Monoclonal Antibody Treatments

$0 member cost-share for

treatment administration*

Prior authorization only required for CPT code Q0221

*Vaccine ingredient cost is still covered directly by Medicare FFS.

Alongside these waivers, the Coronavirus Aid, Relief, and Economic Security (CARES) Act provided for a 20% increase to the inpatient prospective payment system (IPPS) Diagnosis Related Group (DRG) rate for COVID-19 patients for the duration of the public health emergency. This increase applied to claims that included the applicable COVID-19 ICD-10-CM diagnosis code and met the date of service requirement. When the PHE ends on May 11, 2023, these add-on payments will no longer be included for discharge dates of service as of May 12, 2023 and thereafter.

Wellcare is committed to providing a smooth transition for both our members and providers as we resume business as usual. While we will continue to communicate any updates to our business practices directly to our provider partners, we always highly recommend that providers verify member eligibility, benefits, and prior authorization requirements before rendering services.

 

Material ID: PRO_2081305E Internal Approved 05112023 

List effective 7/1/2023

Wellcare Oklahoma requires prior authorization (PA) as a condition of payment for many services. This Notice contains information regarding such prior authorization requirements and is applicable to all Medicare products offered by Wellcare Oklahoma.

Wellcare Oklahoma is committed to delivering cost effective quality care to our members. This effort requires us to ensure that our members receive only treatment that is medically necessary according to current standards of practice. Prior authorization is a process initiated by the physician in which we verify the medical necessity of a treatment in advance using independent objective medical criteria and/or in network utilization, where applicable.

It is the ordering/prescribing provider’s responsibility to determine which specific codes require prior authorization.

Please verify eligibility and benefits prior to rendering services for all members. Payment, regardless of authorization, is contingent on the member’s eligibility at the time service is rendered. NON-PAR PROVIDERS & FACILITIES REQUIRE AUTHORIZATION FOR ALL HMO SERVICES EXCEPT WHERE INDICATED. For complete CPT/HCPCS code listing, please see Online Prior Authorization Tool on our website at https://www.oklahomacompletehealth.com/providers/preauth-check/medicare-pre-auth.html

 

List effective 1/1/2022

Wellcare requires prior authorization (PA) as a condition of payment for many services. This Notice contains information regarding such prior authorization requirements and is applicable to all Medicare products offered by Wellcare.

Wellcare is committed to delivering cost effective quality care to our members. This effort requires us to ensure that our members receive only treatment that is medically necessary according to current standards of practice. Prior authorization is a process initiated by the physician in which we verify the medical necessity of a treatment in advance using independent objective medical criteria and/or in network utilization, where applicable.

It is the ordering/prescribing provider’s responsibility to determine which specific codes require prior authorization.

Please verify eligibility and benefits prior to rendering services for all members. Payment, regardless of authorization, is contingent on the member’s eligibility at the time service is rendered. NON-PAR PROVIDERS & FACILITIES REQUIRE AUTHORIZATION FOR ALL HMO SERVICES EXCEPT WHERE INDICATED.   

For complete CPT/HCPCS code listing, please see Online Prior Authorization Tool on our website at www.oklahomacompletehealth.com/providers/preauth-check/medicare-pre-auth

Effective January 1st, 2023, the following are changes to prior authorization requirements:

 

In an effort to continue promotion of quality improvement for services provided to our members, Ambetter and WellCare of Oklahoma are pleased to announce a partnership with National Imaging Associates, Inc (NIA).

Ambetter, WellCare and NIA encourage our providers to attend an upcoming provider education webinar on the various programs administered by NIA. There are several one-hour webinar sessions that will take place on the following dates.

To register for one these informative webinars, please click the Provider Training link on the Oklahoma Complete Health website.* www.oklahomacompletehealth.com/providers/resources/provider-training.html

*It is recommended but not mandatory that you RSVP at least one week prior to the training that you plan to attend by registering for one of the education sessions above.

You will receive a registration confirmation email from NIA for the Webinar session you selected.  It is recommended that computer access is utilized if possible, to view educational documents during the webinar.  To access the webinar by computer, please click on the link for the session you would like to attend or type the URL address into your browser.  Please see call in instructions below if you do not have computer access.

NIA, Ambetter and Wellcare of Oklahoma look forward to working with you to ensure that your patients, our members receive services delivered in a quality, clinically appropriate fashion.

If you have questions about this bulletin or other provider resources, please contact the Oklahoma Complete Health Provider Support team at:

OklahomaCompleteHealth_PR@OCH.com

Or call Provider Services at:

  •  Ambetter of Oklahoma (Marketplace): 1-833-492-0679 (TTY: 711)
  •  Wellcare Oklahoma (Medicare Advantage): 1-833-853-0865 (TTY: 711)

Beginning on September 1, 2022, Wellcare of Oklahoma will be collaborating with Optum, to ensure consistency in claims review and reimbursement practices with our hospital partners by reviewing all facility claims that exceed outlier thresholds.     

Effective September 1, 2022, will require submission of itemized bills with high dollar facility claims.   You must submit an itemized detail listing each supply and service provided to the patient and match the billed charge amount for the underlying claim for submission of all facility outlier claims.  

Itemized Bill Requirements:

  • The itemized bill must list each supply and services provided to the member, match the dollar amount and date of service of the request. 
  • The request will apply to claims submitted with other insurance, changes in coverage, lapse in coverage, or if the member’s coverage termed during the length of stay. 
  • Interim billing will not require an itemized bill, however it will be requested once the final bill has been submitted.

How will Company communicate its findings?

If Optum identifies any billing issues during its review, it will send you detailed findings regarding these issues and provide you with a direct contact with whom you can discuss and resolve any issues you may have with its findings.  You can also exercise your right to formally appeal Optum’s finding. 

Questions:

If you have questions about this communication, please contact Provider Relations at pr_wellcare_ok@oklahomacompletehealth.com.

Thank you for your continued partnership with Wellcare. As you know, we continually review and update our payment and utilization policies to ensure that they are designed to comply with industry standards while delivering the best patient experience to our members. 

Wellcare is issuing a new policy effective *4/1/2022*.

Policy Number: CC.PP.071

Policy Name: Evaluation and Management Services Billed with Treatment Rooms

Policy Description: Disallows E&M services in treatment rooms as this does not represent a treatment type of service.

Lines of Business: Medicare

For detailed information about this policy, please refer to our Clinical & Payment Policies [link: https://www.wellcareok.com/for-providers/clinical-payment-policies.html]. And for questions about this or any of our payment policies, please don’t hesitate to reach out to our Provider Services team at 1-833-853-0865.

Dear Valued Provider,

To reduce administrative burden on our provider partners, Wellcare is making the following changes to both our peer-to-peer review request requirements and elective medical inpatient authorization process. This will impact peer-to-peer and elective medical inpatient authorization requests received on or after the elective dates outlined below.

Peer-to-Peer Review Requests Change Effective 10/1/2022

In order to ensure accurate delivery and reimbursement for medically necessary services to our members, Wellcare is updating our requirements for peer-to-peer review effective 10/1/2022 to the following:

  • Peer-to-peer review requests will be allowed up to two (2) business days after Integrated Denial Notice or day of discharge, whichever is later.
  • Peer-to-peer outreach will be completed within 2 business days of peer-to-peer review request.
  • If provider is not reached, a voice mail will be left (if possible) giving provider one business day to respond.
  • If the provider does not respond within the stipulated timeframe, Wellcare will be unable to proceed with peer-to-peer request.

No changes are being made to existing peer-to-peer timeframes or processes for pre-service requests.

Elective Medical Inpatient Authorization Process Change Effective 11/1/2022

To provide increased flexibility and better align with industry best practices, we are making the following changes to our elective medial inpatient authorization process effective 11/1/2022:

  • The prior authorization span for elective inpatient admissions will be increased to 60 (sixty) days for dates of service on or after 11/1/2022.
  • If the planned admission date exceeds the authorized date span of 60 days, a new authorization span is required.
  • Elective Inpatient Prior Authorization numbers will now start with the prefix of OP instead of IP.
  • Notification of admission is required within one (1) business day of admit. At the time of admission notification, a new authorization number for the admission will be provided with the IP prefix. Failure to provide timely notification may result in a denial of payment.   

As a reminder, all planned/elective admissions to the inpatient setting require prior authorization. Prior authorization should be requested at least five (5) days before the scheduled service delivery date or as soon as need for service is identified. If prior authorization is not on file at the time of elective admission, the service is considered retrospective, and provider should follow the appropriate retrospective request process as communicated in the provider notice. Emergent admissions do not require prior authorization.

Thank you for continuing to provide our Medicare members with high quality and compassionate care. If you have questions about any of this information, please contact Provider Services.

Sincerely,

Wellcare

As a valued provider partner, we’d like to remind you to review your National Provider Identifier (NPI) data in National Plan & Provider Enumeration System (NPPES) as soon as possible to ensure that accurate provider data is displayed.  As you may know, providers are legally required to keep their NPPES data current. Centers for Medicare & Medicaid Services (CMS) is also encouraging Medicare Advantage Organizations to use NPPES as a resource for our online provider directories.  By using NPPES, we can decrease the frequency by which we contact you for updated directory information and provide more reliable information to Medicare beneficiaries. 

If the NPPES database is kept up to date by providers, our organization can rely on it as a primary data resource for our provider directories, instead of calling your office for this information.  With updated information, we can download the NPPES database and compare the provider data to the information in our existing provider directory to verify its accuracy.

When reviewing your provider data in NPPES, please update any inaccurate information in modifiable fields including provider name, mailing address, telephone and fax numbers, and specialty, to name a few.  You should also make sure to include all addresses where you practice and actively see patients and where a patient can call and make an appointment.  Do not include addresses where you could see a patient, but do not actively practice.  Please remove any practice locations that are no longer in use. Once you update your information, you will need to confirm it is accurate by certifying it in NPPES. Remember, NPPES has no bearing on billing Medicare Fee-For-Service. 

If you have any questions pertaining to NPPES, you may reference NPPES help at https://nppes.cms.hhs.gov/webhelp/nppeshelp/HOME%20PAGE-SIGN%20IN%20PAGE.html.
Please direct any general questions about this notice to your provider relations representative.